|
Quotes & Info
|
| APPA > SEC Filings for APPA > Form 8-K on 1-Oct-2012 | All Recent SEC Filings |
1-Oct-2012
Other Events, Financial Statements and Exhibits
On September 28, 2012, A.P. Pharma, Inc. (the "Company") announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate, APF530, for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV).
(d) Exhibits.
Exhibit No. Document Description
99.1 Press Release issued on September 28, 2012
|
|